Schedule

Wednesday, Nov. 10, 2021

Pre-Conference Programs
*Times and program schedule subject to change. 

World Immunotherapy Council's 4th Young Investigator Symposium
7:30 a.m.–1 p.m. EST*

 

 

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations
2–6 p.m. EST*

Session I: Immunity Beyond T cells
2–3:20 p.m. EST

2 p.m.
Welcome: Unleashing Curiousity, Courage and Conviction for The Next Wave of Immunotherapy
Zhen Su, MD, MBA – Marengo Therapeutics

2:10 p.m. Beyond the Horizon. How Targeting Myeloid cells can Revolutionize Cancer Immunotherapy
Dmitry I. Gabrilovich, MD, PhD AstraZeneca

2:30 p.m. Leveraging B-cell Immunity to Promote PD-1 blockade Effectiveness in Glioblastoma
David Hou – Northwestern University

2:40 p.m. A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence
James B. Trager, PhDNkarta Therapeutics

2:50 p.m. Panel Discussion
Moderator:
Francesco M. Marincola, MD – Kite, A Gilead Company
Panelists:
Dmitry I. Gabrilovich, MD, PhD AstraZeneca
David Hou – Northwestern University
Katy Rezvani, MD, PhD – MD Anderson Cancer Center
James B. Trager, PhD Nkarta Therapeutics

   
Session II: CAR T and other Cell Therapies in Solid Tumors
3:204:30 p.m. EST
 

 
3:20 p.m. Equipping CAR T for Solid Tumors: Challenges and Opportunities
Carl H. June, MD – University of Pennsylvania


3:40 p.m. Secretion of Matrix Metallopeptidase 8 Promotes Tumor Infiltration and Antitumor Activity of CAR T cells
Irfan N. Bandey, PhD – University of Houston

3:50 p.m. AlloCAR TTM Cells Built for Enhanced Expansion, Persistence, and the Ability to Overcome the Solid Tumor Microenvironment
Barbra J. Sasu, PhD – Allogene Therapeutics

4:00 p.m. Debate/Panel Discussion
Moderator: Kald Abdallah, MD, PhD – Bristol Myers Squibb
Panelists: Irfan N. Bandey, PhD – University of Houston
Carl H. June, MD – University of Pennsylvania
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Barbra J. Sasu, PhD – Allogene Therapeutics

4:30 p.m. Break
   
Session III: Novel Combinations
4:456:00 p.m. EST
 

 
4:45 p.m. The Evolving Landscape of Immunotherapy Combinations
Jonathan Cheng, MD – Bristol Myers Squibb

5:05 p.m. Beyond T cells and Bispecific Antibodies for Solid Tumors: Odyssey of Bispecific Antibody (BiAb) Armed Activated T cells (BATs)
Lawrence G. Lum, MD, DSc – University of Virginia

5:15 p.m. INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma
David A. Reardon, MD – Dana-Farber Cancer Institute

5:25 p.m. Panel Discussion
Moderator: Giovanni Melillo, MD – AstraZeneca
Panelists: Jonathan Cheng, MD – Bristol Myers Squibb
Sandra Demaria, MD – Weill Cornell Medicine
Lawrence G. Lum, MD, DSc – University of Virginia
David A. Reardon, MD – Dana-Farber Cancer Institute
                 
5:55 p.m. Closing Remarks
Kald Abdallah, MD, PhD Bristol Myers Squibb


Thursday, Nov. 11, 2021

Pre-Conference Programs
*Times and program schedule subject to change. 

Primer on Tumor Immunology and Cancer Immunotherapy™
8 a.m.–5:30 p.m. EST

Session I: Generating Anti-Tumor Immunity
8–9:55 a.m. EST

8 a.m.
Introduction
Yvonne Saenger, MD – Albert Einstein College of Medicine

8:05 a.m.  The Adaptive Immune Response
Jonathan D. Powell, MD, PhD – Calico

8:35 a.m.  Overview of Innate Immunity in Cancer Immunotherapy and Complexities of Macrophages
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital

9:05 a.m. Role of Dendritic Cells in Cancer
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
9:35 a.m. Session I Panel Discussion 
Moderator:
Yvonne Saenger, MD – Albert Einstein College of Medicine
Panelists: Session I Speakers

9:55 a.m. Break
   
Session II: Approaches to Immunotherapy I
10:10 a.m.–Noon EST

10:10 a.m.
 
Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center

10:40 a.m. Myeloid Derived Suppressor cells: From the Biology to Therapy
Dmitry I. Gabrilovich, MD, PhD – AstraZeneca

11:10 a.m. Cancer Vaccines
Howard L. Kaufman, MD, FACS Amkyra Therapeutics/Massachusetts General Hospital

11:40 a.m. Session II Panel Discussion 
Moderator:
Yvonne Saenger, MD – Albert Einstein College of Medicine
Panelists:
Session II Speakers

Noon Lunch

   
Session III: Approaches to Immunotherapy II
1:30–3:25 p.m. EST
 
 
1:30 p.m.
Introduction
Jennifer L. Guerriero, PhD –
Brigham and Women's Hospital

1:35 p.m. Updates on CAR T Cell Therapies
Carl H. June, MD – University of Pennsylvania

2:05 p.m. Microbiome
Thomas F. Gajewski, MD, PhD – University of Chicago

2:35 p.m. Metabolism in Cancer Immunology and Immunotherapy
Greg M. Delgoffe, PhD – University of Pittsburgh

3:05 p.m. Session III Panel Discussion 
Moderator:
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital
Panelists:
Session III Speakers

3:25 p.m. Break
   
Session IV: Clinical Practice of Immunotherapy
3:40–5:30 p.m. EST


3:40 p.m. Immune Biomarkers to Guide Clinical Care
Yvonne Saenger, MD – Albert Einstein College of Medicine

4:10 p.m. Identification and Management of Immune Related Adverse Events
Anna C. Pavlick, MD, MBA – Weill Cornell Medicine

4:40 p.m. What You Need for a Good TIME (Tumor Immune MicroEnvironment)
James L. Gulley, MD, PhD, FACP – National Cancer Institute

5:10 p.m. Session IV Panel Discussion 
Moderator:
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital
Panelists:
Session IV Speakers

5:25 p.m. Closing Remarks
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital


Immuno-Resistance and Sequencing Symposium
7:30 a.m.–6 p.m. EST

Session I: Novel Primary vs. Adaptive Resistance Mechanisms
7:30–9:15 a.m. EST

7:30 a.m.
Introduction
Samir N. Khleif, MD – Georgetown University Medical Center

7:35 a.m.  Anti-PD1 Resistance - Different Flavors
Samir N. Khleif, MD – Georgetown University Medical Center

7:55 a.m.  Dissecting the Complexity of HLA Loss in Cancer
Christian Hammer, PhD – Genentech, Inc.

8:15 a.m.  Dissecting Evolution of Clinical Immunotherapy Resistance
David Liu, MD, MPH, MSDana-Farber Cancer Institute
8:35 a.m. Immune Checkpoint Therapy: Identification of Resistance Mechanisms
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

8:55 a.m. Session I Panel Discussion 
Moderator:
Ira Mellman, PhD – Genentech, Inc.
Panelists:
Session I Speakers
Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer        
Center

9:15 a.m. Break
   
Session II: Myths vs. Knowledge on Clinical Therapeutic Mechanisms - Lessons Learned
9:30–11:10 a.m. EST


9:30 a.m. Single Agent Trials, Lessons Learned - OX40 Agonists are Still Alive
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center

9:50 a.m. Role of Tim3 in Myeloid Cells
Vijay K. Kuchroo, DVM, PhD – Center for Neurologic Diseases, BWH

10:10 a.m. Anti-PD1 and IDO1 Inhibition:  Lessons Learned
Lance Leopold, MD – Incyte

10:30 a.m. Priming the Immune System to Provoke Checkpoints: The Path to Maintaining the Immunotherapy Momentum
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

10:50 a.m. Session II Panel Discussion
Moderator:
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center
Panelists:
Session II Speakers

   
Session III: Understanding the Biology of Therapeutic Pillars - Targeted Pathways and Future Direction
11:10 a.m.–2:20 p.m. EST

11:10 a.m. VISTA Targeting of T cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
J. Louise Lines, PhD – Dartmouth College

11:30 a.m. Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

11:50 a.m. Lunch Break

1:20 p.m. In Pre-clinical Models Metabolic Manipulations Improve the Efficacy of T cell Immunotherapy of Melanoma
Hildegund Ertl, MD The Wistar Institute

1:40 p.m.
Molecular Mechanisms of T cell Exhaustion and Relevance for Immunotherapy of Cancer
E. John Wherry, PhD – University of Pennsylvania

2:00 p.m.
Session III Panel Discussion
Moderator: E. John Wherry, PhD University of Pennsylvania
Panelists:
Session III Speakers

Session IV: Resistance Reversal Strategies & Sequencing
2:20–4:20 p.m. EST

2:20 p.m. Cellular Mechanisms of Cancer Immunity Response and Resistance
Ira Mellman, PhD – Genentech

2:40 p.m. T cell Activation and Timing 
Benjamin Youngblood, PhD – St. Jude Children's Research Hospital

3 p.m. Mapping Immunosuppressive Cell in the Tumor Microenvironment
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

3:20 p.m. Machine Learning for Spatial Multi-omics in Cancer Immunotherapy
Elana Fertig, PhD – Johns Hopkins University

3:40 p.m. Autophagy and Immunometabolism Regulation of CD8+ T cell Antitumor Immunity
Julian J. Lum, PhD – BC Cancer

4 p.m. Panel Discussion – Rational Combination Design
Moderator:
Samir N. Khleif, MD – Georgetown University Medical Center
Panelists:
Session IV Speakers

4:20 p.m. Break
   
Session V: Developmental Process
4:35–6 p.m. EST
 
 
 4:35 p.m. Novel Immunotherapy Clinical Trial Design
Osama E. Rahma, MD – AstraZeneca

4:55 p.m. Combinations of Agents without Single-agent Activity
Kald Abdallah, MD, PhD – Bristol Myers Squibb

5:15 p.m. Regulatory Considerations for Cancer Immunotherapeutic Development – anti-PD-(L)1 resistance
Marc Theoret, MD – Food and Drug Administration (FDA)

5:35 p.m. Panel Discussion
Moderator:
Kald Abdallah, MD, PhD – Bristol Myers Squibb
Panelists:
Session V Speakers

5:55 p.m. Closing Remarks
Samir N. Khleif, MD – Georgetown University Medical Center


Noon–1:30 p.m. EST

Meet-the-Expert Lunch

6:30–8:30 p.m. EST

Session 1
6:30–7:30 p.m. EST

6:30 p.m.


6:50 p.m.





7:00 p.m.


7:20 p.m.





Session 2
7:30–8:30 p.m. EST

7:30 p.m.


7:45 p.m.







8:15 p.m.

Grant Writing Workshop


Moderator:
Ravi Patel, MD, PhD University of Pittsburgh

Overview of Grant Opportunities
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center

Q&A
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina

Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute


Principles of Grant Writing
Thomas F. Gajewski, MD, PhD – University of Chicago

Q&A
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina

Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute



Moderator:
Ravi Patel, MD, PhD University of Pittsburgh

NCI Officer Tips and Tricks
Lillian Kuo, PhD National Cancer Institute

Mock Study Section
Scientific Review Officer: Lillian Kuo, PhD – National Cancer Institute
Chair: Thomas F. Gajewski, MD, PhD – University of Chicago
Primary Reviewer: Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Secondary Reviewer: Ravi Patel, MD, PhD – University of Pittsburgh
Statistical Reviewer Elizabeth Hill, PhD – Medical University of South Carolina


Q&A
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina

Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute


Friday, Nov. 12, 2021

Annual Meeting

7 a.m.–8:30 p.m. EST*
*Times and program schedule subject to change. 

7 a.m.–8:30 p.m. EST

Poster and Exhibit Hall

Presidential Welcome & Awards Ceremony
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
7:45–8:25 a.m EST

7:45 a.m.

Presidential Welcome
Patrick Hwu, MD – Moffitt Cancer Center

7:55 a.m.

Rosenberg Scholar

8:05 a.m.

Academy of Immuno-Oncology Awards

8:15 a.m.

2022 Richard V. Smalley

8:20 a.m.

Lifetime Achievement

Session 100: Update Session
8:25–8:55 a.m. EST

8:25 a.m.

Food and Drug Administration
Adnan Jaigirdar, MD, FACS Food and Drug Administration

8:40 a.m.

Food and Drug Administration

Session 101: Update Session
8:35–9:05 a.m. EST

 

 

Session 101: Keynote Address
Chair:
Patrick Hwu, MD –
Moffitt Cancer Center
9:05–9:55 a.m. EST

9:05 a.m.

Introduction
Patrick Hwu, MD – Moffitt Cancer Center

9:10 a.m. 

Neutralizing Protumor Inflammation: Lessons Learned from Preclinical Mouse Models
Lisa M. Coussens, PhD – Oregon Health & Science University

9:50 a.m.

Question and Answer
Lisa M. Coussens, PhD – Oregon Health & Science University

9:55–10:10 a.m. EST

Break

Session 102: Myeloid Cells
Co-Chairs: 
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Miriam Merad, MD, PhD –
Icahn School of Medicine at Mount Sinai
10:10 a.m.–12:10 p.m. EST

10:10 a.m.

Introduction
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

10:15 a.m.

Myeloid Cells
Shannon J. Turley, PhD Genentech

10:35 a.m.

Trem2 in Cancer
Marco Colonna, MD – Washington University School of Medicine

10:55 a.m.

Macrophages 
Maria Casanova-Acebes, PhD – Icahn School of Medicine at Mount Sinai

11:15 a.m.

CD40
Robert H. Vonderheide, MD, DPhil University of Pennsylvania Perelman School of Medicine

11:35 a.m.

(676) Altered circulating myeloid states associated with anti-PD-1 resistance induce T cell paralysis in human biliary cancer
Bridget P. Keenan, MD, PhD University of San Francisco

11:45 a.m.

(209) Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Antitumor Immunity
Sabina Kaczanowska, PhD National Cancer Institute

11:55 a.m.

(664) Pulmonary priming of tumor-reactive CD8+ T cells by DC1 is impaired by regulatory T cells
Maria Zagorulya, BS – Massachusetts Institute of Technology

12:05 p.m.

Closing Remarks
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine

Session 103: Late-Breaking Abstract Sessions
12:10–12:40 p.m. EST

 

 

12:40–2:10 p.m. EST

Lunch and Poster Viewing

Concurrent Rapid Oral Abstract Presentation Session 104: Basic Research
Co-Chairs:
Aitziber Buque Martinez, PhD Weill Cornell Medical College
Abigail Overacre-Delgoffe, PhD – University of Pittsburgh

12:55–1:55 p.m. EST

12:55 p.m.

(805) Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice
Margaret L. Axelrod, BS Vanderbilt University

1:03 p.m.

(700) Increasing MHC-I expression to potentiate immune checkpoint blockade therapy
Shengqing Gu, PhD Dana-Farber Cancer Institute

1:11 p.m.

(310) T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
Yuki Muroyama, MD, PhD University of Pennsylvania Perelman School of Medicine

1:19 p.m.

Question and Answer

1:25 p.m.

(693) Mucosal-Associated Invariant T (MAIT) Cell Regulation Networks in Anti-Tumor Immunity
Benjamin Ruf, MD National Institutes of Health

1:33 p.m.

(805) Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients Studies of sexual immune dimorphism in the tumor microenvironment
Dhifaf Sarhan, PhD Karolinska Institutet

1:41 p.m.

(651) Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction
Frank Lowery III, PhD National Cancer Institute

1:49 p.m.

Question and Answer

Concurrent Rapid Oral Abstract Presentation Session 105: Clinical
Co-Chairs:
Allison Betof, MD, PhD – Memorial Sloan Kettering Cancer Center
Rafeh Naqash, MD – National Cancer Institute/NIH
12:55–1:55 p.m. EST

12:55 p.m.

(457) KEYNOTE-495/KeyImPaCT: interime analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC)
Martin Gutierrez, MD Hackensack Meridian Health

1:03 p.m.

(300) Longitudinal plasma proteomic profiling of non-small cell lung cancer patients undergoing immune checkpoint blockade-based therapy
Michal Harel, PhD Oncohost LTD

1:11 p.m.

(832) Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
John-William Sidhom, MD, PhD Johns Hopkins University School of Medicine

1:19 p.m.

Question and Answer

1:25 p.m.

(503) Clinical Activity of ICT01, an anti-BTN3A-Targeting, γ9δ2-Activating mAb, Alone and in Combination with Pembrolizumab in Patients with Advanced/Refractory Solid Tumors: EVICTION Trial
Martin Wermke Uniklinikum Dresden

1:33 p.m.

(379) Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB)
Emily Z. Keung, MD, MA The University of Texas MD Anderson Cancer Center

1:41 p.m.

(354) Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study
Vicky Makker, MD Memorial Sloan Kettering Cancer Center

1:49 p.m.

Question and Answer

Concurrent Session 106: Exhaustion vs. stem-like TILs – TILs classification
Co-Chairs:
Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center
Catherine J. Wu, MD –
Dana-Farber Cancer Institute
2:10–3:25 p.m. EST

2:10 p.m.

TBA
Alena Gros, PhD – Vall d'Hebron Institute of Oncology

2:35 p.m.

Transcriptional Strategies to Counter T Cell
Patrick G. Hogan, PhD La Jolla Institute of Immunology

3:00 p.m.

(Re)modeling Melanoma Tumor Infiltrating Lymphocytes
Niroshana Anandasabapathy, MD, PHD – Weill Cornell Medicine

Concurrent Session 107: Re-Imagine Patient Access and Care Delivery in the Era of Digital Medicine
Co-Chairs: 
Lynda Chin, MD – Dell Medical School and Apricity Health LLC
Patricia Brown, JD – Medically Home Group
2:10–3:25 p.m. EST

2:10 p.m.

Overview of the Landscape and Future of Digital Medicine
Lynda Chin, MD – Dell Medical School and Apricity Health

2:25 p.m.

Precision in Care Delivery and Therapeutic Development in the Era of Digital Medicine
Sean Khozin, MD, MPH – CancerLinQ

2:40 p.m.

Bio/Pharma perspectives
Rasika Kalamegham, PhD Genentech Roche

2:55 p.m.

Innovation/Startup perspective
Patricia Brown, JD – Medically Home Group

3:10 p.m.

Panel Discussion

Concurrent Session 108: NK Cells
Co-Chairs: 
Lewis L. Lanier, PhD – University of California San Francisco
Katy Rezvani, MD, PhD –
The University of Texas MD Anderson Cancer Center
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

2:15 p.m.

Natural Killer Cell Diversity and Activation
Lewis L. Lanier, PhD – University of California San Francisco

2:30 p.m.

Tumor Infiltrating NK Cells
Heidi Cerwenka – University of Heidelberg

2:45 p.m.

Adaptive NK Cells
Karl-Johan Malmberg, MD, PhD – Oslo University Hospital

3 p.m.

CRISPR-edited NK Cells
May Daher, MD – The University of Texas MD Anderson Cancer Center

3:15 p.m.

(216) Multiplex base editing of NK cell to enhance cancer immunotherapy
Minjing Wang, BSc University of Minnesota

Concurrent Session 109: Biomarkers, TLS (Early Trials and Translational Research, Tissue Access Aspects)
Co-Chairs:
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center
Alessandra Cesano, MD, PhD –
ESSA Pharma Inc.
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center

2:15 p.m.

Tumor Biomarkers
Priti S. Hegde, PhD – Foundation Medicine

2:33 p.m.

Pronostic and Predictive Value of Tertiary Lymphoid Structures in Human Cancers
Catherine Sautes-Fridman, PHD – Centre de Recherche des Cordeliers

2:51 p.m.

Host Biomarkers (Microbiome)
Christine Spencer, PhD Parker Institute for Cancer Immunotherapy

3:09 p.m.

(76) Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy
Bryan Iorgulescu, MD Dana-Farber Cancer Institute

Concurrent Session 110: Microbiome, Metabolism and ER Stress
Co-Chairs:
Laurie H. Glimcher, MD – Dana-Farber Cancer Institute
Jennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center

2:10–3:25 p.m. EST

2:10 p.m

Overview
Jennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center

2:15 p.m.  

ER Stress
Juan R. Cubillos-Ruiz, PhD – Weill Cornell Medicine

2:30 p.m.

Microbiome
Wendy Garrett, MD  – Harvard School of Public Health

2:45 p.m.

Metabolomics
Weiping Zou, MD, PhD – University of Michigan

3:00 p.m. 

(839) Microbiota-specific T follicular helper cells drives tertiary lymphoid structure formation and anti-tumor immunity in colorectal cancer
Abigail Overacre-Delgoffe, PhD – University of Pittsburgh

3:05 p.m.

(668) Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8+ T cells
Teresa Manzo, PhD – IEO

3:10 p.m.

Question and Answer

Concurrent Session 111: Intratumoral Therapy at a Crossroads
Co-Chairs: 
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Ichan School of Medicine at Mount Sinai
Adi Diab, MD –
The University of Texas MD Anderson Cancer Center
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Ichan School of Medicine at Mount Sinai

2:15 p.m.

State of the Field and Recent Trials
Adi Diab, MD – The University of Texas MD Anderson Cancer Center

2:25 p.m.

Standards for Intratumoral Therapies
Aurelien Marabelle, MD, PhD – Gustave Roussy

2:35 p.m.

Endpoints for Efficacy
Ignacio Melero, MD, PhD FIMA, Clinica Universidad de Navarra

2:45 p.m.

Igniting the Fire: Intratumoral Therapy to Turn on Immune Response to Cancer
Antoni Ribas, MD, PhD – University of California Los Angeles

2:55 p.m.

Panel Discussion
Aurelien Marabelle, MD, PhD – Gustave Roussy
Ignacio Melero, MD, PhD – FIMA, Clinica Universidad de Navarra
Joshua Brody, MD – Ichan School of Medicine at Mount Sinai
Antoni Ribas, MD, PhD – University of California Los Angeles
Robert Andtbacka, MD, CM, FACS, FRCSC – Seven and Eight Biopharmaceuticals
Stephen Solomon, MD – Memorial Sloan Kettering Cancer Center
Craig L. Slingluff, MD – University of Virginia School of Medicine
Silvia Formenti, MD – Weill Cornell Medicine

Session 112: Debate: Engineered vs. Endogenous T cells
Co-Chairs: 
Alex Marson, MD, PhD – University of California San Francisco
Cassian Yee, MD –
The University of Texas MD Anderson Cancer Center
3:25–4:35 p.m. EST

3:25 p.m.

Endogenous T cells
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

3:40 p.m.

Targeting Solid Malignancies with "Public" Neoantigen-Specific T Cells
Christopher A. Klebanoff, MD – Memorial Sloan Kettering Cancer Center

3:55 p.m.

Reprogramming T cell therapies with CRISPR
Alexander Marson, MD, PhD – University of California San Francisco

4:10 p.m.

Engineered T cells Engineering Next Generation CAR-T Cells for Cancer
Yvonne Chen, PhD – University of California Los Angeles

4:25 p.m.

Panel Debate
Yvonne Chen, PhD – University of California Los Angeles
Christopher A. Klebanoff, MD – Memorial Sloan Kettering Cancer Center
Alexander Marson, MD, PhD – University of California San Francisco
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

4:35–4:50 p.m. EST

Break

Session 113: Debate: Declassification/deconvolution of T cell types
Co-Chairs: 
Ira Mellman, PhD – Genentech, Inc.
Ansuman Satpathy, MD, PhD – Stanford
4:50–6 p.m. EST

4:50 p.m.

Introduction
Ansuman Satpathy, PhD Stanford University

4:55 p.m.

Brief Summary – Exhaustion Side
E. John Wherry, PhD University of Pennsylvania

5:05 p.m.

Brief Summary – Non-Exhausted Side
Andrea Schietinger, PhD Memorial Sloan Kettering Cancer Center

5:15 p.m.

Panel Debate
E. John Wherry, PhD University of Pennsylvania
Drew M. Pardoll, MD, PhD Johns Hopkins University
Haydn Kissick, PhD –
Emory University
Andrea Schietinger, PhD Memorial Sloan Kettering Cancer Center

Session 115: Poster Symposium
Co-Chairs:
Diwakar Davar, MD UPMC Hillman Cancer Center
Amanda Lund, PhD NYU Grossman School of Medicine
6–7 p.m. EST

6:00 p.m.

(30) Blood-based Glycoprotein Signatures in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Receiving First-Line Immune Checkpoint Blockade
Klaus Lindpaintner, MD, MPH InterVenn

6:10 p.m

(748) Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade
Sruthi Ravindranathan, PhD, MS Emory University

6:20 p.m.

(663) Media based on the metabolic composition of tumor intersitial fluid reveals persistent T cell dysfunction induced through arginine deprivation and exposure to the oncometabolite
Yupeng Wang, BS University of Pittsburgh

6:30 p.m.

(683) Type-I-interfereon activates cross-dressed CD11b+ conventional dendritic cells to enhance anti-tumor immuity
Ellen Duong, ScB Koch Institute

6:40 p.m.

(66) Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients with single agent immunotherapy
Afaf Abed, MBBS, FRACP Edith Cowan University

6:50 p.m.

Question and Answer

7–8:30 p.m. EST

Poster Reception

Saturday, Nov. 13, 2021

Annual Meeting

7:15 a.m.–8 p.m. EST*
*Times and program schedule subject to change. 

7 a.m.–8:30 p.m. EST

Poster and Exhibit Hall

Session 200: SITC Business Meeting
Chair:
Patrick Hwu, MD  – Moffitt Cancer Center
7:15–7:45 a.m. EST

Organizer Welcome
8–8:05 a.m. EST

Awards Ceremony
8:05–8:25 a.m. EST
Chair:
TBA

8:05 a.m.

Tara Withington Public Service

8:10 a.m.

Team Science

8:15 a.m.

Service to JITC

8:20 a.m.

2021 JITC Best Paper

Session 201: Update Session
8:25–9:05 a.m. EST

8:25 a.m.

Journal for ImmunoTherapy of Cancer (JITC) Update
Pedro J. Romero, MD University of Lausanne & University Hospital of Lausanne

8:35 a.m.

National Cancer Institute (NCI) Update

8:50 a.m.

Remembrance of Drs. Martin 'Mac' Cheever and Thomas Waldmann

Session 202: Richard V. Smalley Memorial Award and Lectureship
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
9:05–9:55  a.m. EST

9:05 a.m.

Introduction & 2021 Richard V. Smalley Memorial Award and Lectureship Recognition
Patrick Hwu, MD – Moffitt Cancer Center

9:10 a.m.

CAR-T Cells for Solid Tumors: Charting a Path Forward
Crystal Mackall, MD – Stanford University

9:50 a.m.

Question and Answer
Crystal Mackall, MD – Stanford University

9:55 – 10:10 a.m.

Break

Session 203: COVID Immunobiology/Immunology
Co-Chairs: 
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
Kizzmekia Corbett, PhD –
National Institutes of Allergy and Infectious Diseases, NIH
10:10 a.m.–Noon EST

10:10 a.m.

Immune Memory to COVID-19 Infection
Rafi Ahmed, PhD Emory University

10:30 a.m.

Correlates of Protection

10:50 a.m.

Antibody Responses in Myeloma Patients
Samir Parekh, MD – Mount Sinai School of Medicine

11:10 a.m.

T-cell Responses to COVID-19

11:30 a.m.

(625) COVID-19 vaccination in patients with renal cancer or melanoma receiving immune checkpoint inhibitors
Hannah E. Dzimitrowicz, MD Duke Cancer Center

11:45 a.m.

(626) Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history
Lau Mai Chan, PhD Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR)

12:00 p.m.

Closing Remarks

Session 204: Late-Breaking Abstract Session
Noon–12:30 p.m. EST

12:30–2 p.m. EST

Lunch and Poster Viewing

Concurrent Rapid Oral Abstract Presentation Session 205: Basic Research
Co-Chairs:
Kristin G. Anderson, PhD Fred Hutchinson Cancer Research Center
Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School
12:45–1:45 p.m. EST

12:45 p.m.

(43) Intravital multiphoton imaging of infiltrating CD8 T cell metabolism during immunotherapy in a murine melanoma model
Alexa R. Heaton, PhD Morgridge Institute of Research, University of Wisconsin

12:53 p.m.

(658) CD8 T cell activation in cancer is comprised of two distinct phases
Nataliya Prokhnevska, BS Emory University

1:01 p.m.

(660) Targeting T cell fates: converting exhaustion to memory to improve immunotherapeutic responses to cancer
Nicole E. Scharping, PhD University of California San Diego

1:09 p.m.

Question and Answer

1:15 p.m.

(936) Stromal remodeling regulates dendritic cell abundance in the tumor microenvironment
Anthanasios Papadas, MD University of California San Diego

1:23 p.m.

(601) Sequencing Immunotherapy Before Lymphatic Ablation Unleashes cDC1-Dependent Antitumor Immunity in HNSCC
Robert Saddawi-Konefka, MD, PhD University of California San Diego School of Medicine

1:31 p.m.

(125) Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma
Jessica Lake, MD, MPH University of Colorado Anschutz Medical Campus

1:39 p.m.

Question and Answer

Concurrent Rapid Oral Abstract Presentation Session 206: Clinical
Co-Chairs:
Praveen Bommareddy, MS, PhD Replimune Inc.
Chris Langsdorf Thermo Fisher Scientific
12:45–1:45 p.m. EST

12:45 p.m.

(493) First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40x4-1BB (GEN1042) in patients with advanced solid tumors
Melissa L. Johnson, MD Sarah Cannon Research Institute

12:53 p.m.

(350) Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
Douglas G. McNeel, MD, PhD Carbone Cancer Center, University of Wisconsin

1:01 p.m.

(449) Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with liscabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy
Jerill Thorpe, MS Bristol Myers Squibb

1:09 p.m.

Question and Answer

1:15 p.m.

(374) A Phase IB trial of ziv-afilibercept plus pembrolizumab in patients with advanced solid tumors
Kevin Tyan, BA Harvard Medical School

1:23 p.m.

(529) Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors
Eric Van Cutsem, MD, PhD University Hospital Gathiusberg Leuven

1:31 p.m.

(490) Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors
Elaine Shum, MD New York University Langone Health

1:39 p.m.

Question and Answer

Session 208: Presidential Session
Chair: 
Patrick Hwu, MD – Moffitt Cancer Center
2–3:25 p.m. EST

2:00 p.m.

Introduction
Patrick Hwu, MD Moffitt Cancer Center

2:05 p.m.

(592) ATR-mediated CD47 and PD-L1 upregulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Rodney Cheng-En Hsieh, MD The University of Texas MD Anderson Cancer Center

2:20 p.m.

(900) Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner
Anand V. Kornepati University of Texas Health Science Center San Antonio

2:35 p.m.

Expert Discussant
Sandra Demaria, MD Weill Cornell Medicine

2:45 p.m.

(152) Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages
Taylor L. Wilson, BS St. Jude Children's Research Hospital

3:00 p.m.

(328) Batf3 dendritic cells and 4-1BB/4-1BB ligand axis are required at the effector phase within tumor microenvironment for anti0PD-L1 efficacy
Andrea Ziblat, PhD University of Chicago

3:15 p.m.

Expert Discussant
E. John Wherry, PhD University of Pennsylvania

3:25–3:40 p.m. EST

Break

Concurrent Session 208: Locoregional Therapies, Including Radiation, Oncolytic Viruses and Innate Immune Modulators
Co-Chairs: 
James W. Welsh, MD – The University of Texas MD Anderson Cancer Center
Dimitriy Zamarin, MD, PhD –
Memorial Sloan Kettering Cancer Center
3:40–4:55 p.m. EST

3:40 p.m.

Using Low Dose Radiation and Nanoparticles to address PD1 Resistance
James W. Welsh, MD – The University of Texas MD Anderson Cancer Center

4 p.m.

Modulation of Anti-Tumor Immunity with Oncolytic Viruses
Dimitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

4:20 p.m.

Modulators of Tumor Antigenicity by Radiation Therapy
Nils Rudqvist, PhD – The University of Texas MD Anderson Cancer Center

4:30 p.m.

(768) Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice
Caitlyn Miller, PhD Candidate Stanford University

4:40 p.m.

(758) High-potency synthetic STING agonists rewire the myeloid stroma in the tumor microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma
Akash R. Boda, MS The University of Texas MD Anderson Cancer Center

4:50 p.m.

Questions

Concurrent Session 209: Single Cell Approaches to Advancing Understanding of Immunotherapy Resistance
Co-Chairs:
Kellie N. Smith, PhD – Johns Hopkins School of Medicine
Daniel K. Wells, PhD –
Parker Institute for Cancer Immunotherapy
3:40–4:55  p.m. EST

3:40 p.m.

Introduction

3:45 p.m.

Keynote
Ansuman Satpathy, MD, PhD Stanford University School of Medicine

4:10 p.m.

Longitudinal Single Cell Genomics Reveals Mechanisms of Resistance to Combination Immune Checkpoint Blockade
Alexander Huang, MD University of Pennsylvania

4:20 p.m.

Single Cell Genomics Reveals Resistance Mechanisms of CAR-T Therapy for ALL
Zinaida Good, PhD Stanford University

4:30 p.m.

Epigenomic Features of Exhausted T-cells During Immunotherapy
Debattama Sen, PhD Massachusetts General

4:40 p.m.

(655) Landscape of helper and regulatory CD4+ T cells in melanoma
Giacomo Oliveira, PhD Dana-Farber Cancer Institute

4:50 p.m.

Closing Remarks

Concurrent Session 210: Novel Targets, Resistance Mechanisms
Co-Chairs: 
Jason J. Luke, MD, FACP – UPMC
Irving L. Weissman, MD – Stanford University
3:40–4:55 p.m. EST

3:40 p.m.

Targeting Glycobiology as a Therapeutic Approach in Cancer Immunotherapy
Carolyn Bertozzi, PhD Stanford University

3:55 p.m.

Normal and Neoplastic Stem Cells
Irving L. Weissman, MD – Stanford University

4:10 p.m.

Moving Beyond First Generation STING Agonist Approaches
Jason J. Luke, MD, FACP – UPMC Hillman Cancer Center

4:25 p.m.

Flanking Solid Tumors via Immune-Mediated Disruption of Desmoplastic Stroma
Ellen Pure, PhD University of Pennsylvania

4:40 p.m.

(261) A functional genetic screen uncovers regulators of intratumoral macrophages function and reveals CD24 as a novel target for cancer immunotherapy by macrophages
Amira Barkal, MD, PhD Brigham & Women's Hospital

Concurrent Session 211: Team Science to Catalyze Advancements in Research
Co-Chairs: 
Luis A. Diaz, MD – Memorial Sloan Kettering Cancer Center
Mark Stewart, PhD –
Friends of Cancer Research
3:40–4:55 p.m. EST

3:40 p.m.

TMB – Pro
Luc Morris, MD Memorial Sloan Kettering Cancer Center

3:55 p.m.

High TMB Fails to Predict Immune Checkpoint Blockade Response in All Cancer Types
Daniel J. McGrail, PhD The University of Texas MD Anderson Cancer Center

4:10 p.m.

KN158 TMB Data
Aurelien Marabelle, MD, PhD Gustave Roussy

4:25 p.m.

Diagnostic Perspective
Yardena Samuels, PhD – Weizmann Institute of Science

4:40 p.m.

Panel Discussion
Aurelien Marabelle, MD, PhD Gustave Roussy
Daniel J. McGrail, PhD The University of Texas MD Anderson Cancer Center
Luc Morris, MD Memorial Sloan Kettering Cancer Center
Alexandra Snyder, MD Merck & Co., Inc
Yardena Samuels, PhD – Weizmann Institute of Science

Concurrent Session 212: Cellular Therapies
Co-Chairs: 
Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center
Philip D. Greenberg, MD –
Fred Hutchinson Cancer Center
3:40–4:55 p.m. EST

3:40 p.m.

(561) Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer
Kristin G. Anderson, PhD Fred Hutchinson Cancer Center

3:55 p.m.

(578) CD8-targeting IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
Robert D. Schreiber, PhD –  Washington University School of Medicine

4:10 p.m.

(117) FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy
Bryan Hancock, PhD Fate Therapeutics

4:25 p.m.

(221) CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors
Rebecca C. Larson, BS Jounce Therapeutics

4:40 p.m.

(132) HLA-independent T cell receptors effectively target low abundance antigens
Jorge Mansilla-Soto, PhD Memorial Sloan Kettering Cancer Center

Concurrent Session 213: A Multidisciplinary Approach to Neoadjuvan, Intralesional, and Cell-based Immunotherapy
Co-Chairs: 
Genevieve Boland, MD, PhD Massachusetts General Hospital
Kelly Olino, MD, FACS Yale School of Medicine
3:40–4:55 p.m. EST

3:40 p.m. Neoadjuvant Immunotherapy in Sarcoma
Christina Roland, MD The University of Texas MD Anderson Cancer Center
3:55 p.m. Intralesional Treatment in Head and Neck Cancer
Sara Pai, MD, PhD Massachusetts General Hospital/Harvard
4:15 p.m. T cell-based Immunotherapy for Metastatic Breast Cancer
Stephanie Goff, MD National Cancer Institute
4:30 p.m. (492) Phase 2 efficacy and safety of autologus tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naive patients with advanced cancers
David O'Malley –  OSU Medical Center

4:40 p.m. (337) Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic duravlumab
Craig Slingluff, MD University of Virginia
4:50 p.m.
Closing Remarks

4:55–5:10 p.m. EST

Break

Concurrent Session 214: Radiomics & Imaging
Co-Chairs: 
Neeta Pandit-Taskar, MD – Memorial Sloan Kettering Cancer Center
Ian A. Wilson, PhD –
ImaginAb Inc.
5:10–6:25 p.m. EST

 5:10 p.m.

CT Radiomics in Immuno-Oncology Clinical Development for Lung Cancer
Qin Li, MD, PhD AstraZeneca

 5:35 p.m.

Emerging Technologies to Image  Immune Cell Changes in  Response to Therapy
Elisabeth de Vries, MD, PhD University of Groningen

 6:00 p.m.

Cell Labelling Methods to Track Immune Cells
Peter Choyke, MD   National Institutes of Health

Concurrent Session 215: Clinical Considerations for Toxicity Management and Survivorship
Co-Chairs: 
Marc S. Ernstoff, MD – National Institute of Health
Mary-Kate Kasler, DNP –
Memorial Sloan Kettering Cancer Center
5:10–6:25 p.m. EST

5:10 p.m.

Clinical Considerations for Immune Checkpoint Inhibitor Toxicity Management and Survivorship
Marianne Davies, DNP, AOCNP Yale School of Nursing

5:30 p.m.

Survivorship & Toxicity Management – Physician Perspective
Jarushka Naidoo, MBBCH, MHS – Johns Hopkins Sidney Kimmel Cancer Center

5:50 p.m.

(234) Distinct efficacy and immunological responses to to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in aged versus young hosts
Myrna G. Garcia, BS UTHSA

6 p.m.

(806) PD-1 blockade affects inflammation and metabolic flexibility to potentially mediate cardiac immune-related adverse events
Steven M. Bronson, DVM Wake Forest School of Medicine

6:10 p.m.

(814) Cutaneous Immune-related Adverse Events are Protective of Mortality in Patients Treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study
Yevgeniy R. Semenov, MD Massachusetts General Hospital, Harvard Medical School

6:20 p.m.

Expert Discussant
Igor Puzanov, MD, MSCI, FACP Roswell Park Comprehensive Cancer Center

Concurrent Session 216: Exosomes and Cellular Engineering
Co-Chairs:
Sriram Sathyanarayanan, PhD – Codiak BioScience
Helen E. Heslop, MD –
Baylor College of Medicine
5:10–6:25 p.m. EST

5:10 p.m.

Towards Tumor-Specificity: Engineering CAR T cells to Target the Tn-glycopeptidome
Avery D. Posey, PhD –  University of Pennsylvania School of Medicine

5:30 p.m.

Next-Generation Approaches
Marcela V. Maus, MD, PhD Massachusetts General Hospital

5:50 p.m.

Developing Engineered Exosome Based Therapeutics for Immuno-Oncology
Sriram Sathyanarayanan, PhD – Codiak Biosciences

6:10 p.m.

(130) Engineered natural killer cells reactively block TGIT and CD73 in the GBM microenvironment
Kyle B. Lupo, BS Purdue University

Concurrent Session 217: Neoadjuvant Therapies
Co-Chairs: 
Christian U. Blank, MD The Netherlands Cancer Institute
Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center
5:10–6:25 p.m. EST

5:10 p.m.

B cells/TLS
Tullia C. Bruno, PhD University of Pittsburgh

5:30 p.m.

Neoadjuvant in Melanoma: The Perfect Model
Georgina Long, MBBS, PhD, BSc, FRAC The University of Sydney

5:50 p.m.

Immune Repertoire T cell Overview in Neoadjuvant Immunotherapy
Kellie N. Smith, PhD Johns Hopkins School of Medicine

6:10 p.m.

Panel Discussion
Tullia C. Bruno, PhD University of Pittsburgh
Georgina Long, MBBS, PhD, BSc, FRAC The University of Sydney
Kellie N. Smith, PhD Johns Hopkins School of Medicine

Concurrent Session 218: Immune Checkpoints – New Indications, Mechanisms, and Controversies
Co-Chairs:
Piers J. Ingram, PhD – Hummingbird Bioscience Pte Ltd
Paolo A. Ascierto, MD –
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
5:10–6:25 p.m. EST

5:10 p.m.

VISTA: a promising target for cancer immunotherapy
Piers J. Ingram, PhD Hummingbird Bioscience Pte Ltd

5:30 p.m.

Adenosine pathway as new possible target for immunotherapy
John Stagg, PhD CHUM Research Centre

5:50 p.m.

Is Anti-LAG-3 the Next Effective Immunotherapy Treatment? Certainties and Controversies
Paolo A. Ascierto, MD – Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

6:10 p.m.

(270) Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis
Jessica D. Mackert, PhD Wake Forest University

6:30–7 p.m. EST

Award Ceremony

7–8:30 p.m. EST

Poster Viewing

8:30–11:30 p.m. EST

The CheckPoints Party

Sunday, Nov. 14, 2021

Annual Meeting

8 a.m.–2:20 p.m. EST*
*Times and program schedule subject to change. 

Organizer Welcome
8–8:05 a.m. EST

Medal of Honor Award and Project Lightspeed
8:05–8:30 a.m. EST
Chair:

8:05 a.m.

Introduction
Patrick Hwu, MD Moffitt Cancer Center

8:10 a.m.

Project Lightspeed
Ugur Sahin, MD BioNTech
Özlem Türeci, MD
BioNTech

Session 300: Novel bispecifics
Co-Chairs:
Ann F. Cheung, PhD – Dragonfly Therapeutics, Inc.
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.
8:30–10:30 a.m. EST

8:30 a.m.

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Solid Tumors
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

8:52 a.m.

From Classical Antibody to Novel Multispecific Biologics: Applications to T and NK cell Engagers
Marielle Chiron Cluster, PhD Sanofi

9:15 a.m.

Tetravalent Bispecifics: Next Generation Cancer Therapy to Overcome Immune Evasion
Michelle Morrow, PhD – F-Star Therapeutics

9:37 a.m.

MObilizing the Immune System with Bispecific Antibodies and Engineered Cytokinnes
John R. Desjarlais, PhD – Xencor

10 a.m.

Lessons learned and forward-looking perspectives on bi-/multi-specifics
Marielle Chiron Cluster, PhD Sanofi
John R. Desjarlais, PhD – Xencor

Michelle Morrow, PhD – F-Star Therapeutics
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

10:30 – 10:45 a.m. EST

Break

Concurrent Session 301: Hot Topic Symposium: RNA Vaccines: from COVID back to Cancer
10:45 a.m.–12:15 p.m. EST
Co-Chairs:
Ugur Sahin, MD BioNTech SE
Tal Zaks, MD, PhD Moderna

 

 

Concurrent Session 302: Hot Topic Symposium: ODAC and Accelerated Approvals
10:45 a.m.–12:15 p.m. EST
Co-Chairs:
Alessandra Cesano, MD, PhD ESSA Pharma Inc.
Daniel S. Chen, MD, PhD
Leisha A. Emens, MD, PhD UPMC Hillman Cancer Center

10:45 a.m.

Introduction
Leisha A. Emens, MD, PhD UPMC Hillman Cancer Center

10:50 a.m.

FDA

11:05 a.m.

Clinical/ODAC Member

11:20 a.m.

Biostatistics

11:35 a.m.

Pharma Regulatory Affairs
Scot Ebbinghaus, MD Merck

11:50 a.m.

Panel Discussion

12:15–12:45 p.m.

Break

Session 303: Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment
Co-Chairs:
Margaret K. Callahan, MD, PhD – Memorial Sloan Kettering Cancer Center
Samit Hirawat, MD – Bristol Myers Squibb
12:45–2:45 p.m. EST

12:45 p.m.

Introduction

12:50 p.m.

Coronavirus, Cancer, and Immunotherapy: Navigating Clinical trials and Treatment - Clinician Perspective
Jeffrey Weber, MD, PhD – NYU Langone Medical Center

1:15 p.m.

Perspectives on Virtual Clinical Trials - A new normal post-COVID
Kannan Natarajan, PhD – 
Pfizer

1:40 p.m.

FDA Perspective: Cancer Clinical Trials During Covid-19 Pandemic
Lorraine Pelosof, MD, PhD – Food and Drug Administration

2:05 p.m.

Impact of COVID on Clinical Trials and their Conduct
Kannan Natarajan, PhD – Pfizer
Lorraine Pelosof, MD, PhD – Food and Drug Administration
Jeffrey Weber, MD, PhD – NYU Langone Medical Center

2:45–3 p.m.

Break

Session 304: Phase-Dependent Regulatory Consideration in Manufacturing of Cellular Therapy Products
3 p.m.–4:30 p.m.
Co-Chairs:
Emily Hopewell, PhD Indiana University
Alessandra Cesano, MD, PhD ESSA Pharma, Inc.
Cecila Yeung, MD Fred Hutchinson Cancer Research Center
Raj K. Puri, MD, PhD
Food and Drug Administration

3:00 p.m.

FDA - Phase-dependent regulatory considerations for potency assays of unmodified and/or gene-modified cell therapy products
Kimberly Schultz, PhD Food and Drug Administration

3:20 p.m.

Regulatory Considerations for Late-Stage Manufacturing of Cellular and Gene Therapy Products
Matthew Klinker, PhD Food and Drug Administration

3:40 p.m.

Transformations of potency/manufacturing throughout development - Gene Modified
Sugu Patro Kite, A Gilead Company

3:55 p.m.

Transformations of potency/manufacturing throughout development - Unmodified agents

4:10 p.m.

Panel Discussion
Matthew Klinker, PhD Food and Drug Administration
Sugu Patro Kite, A Gilead Company
Kimberly Schultz, PhD Food and Drug Administration


Schedule At-a-Glance

Wednesday, Nov. 10
Pre-Conference Programs


World Immunotherapy Council's 4th Young Investigator Symposium

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Thursday, Nov. 11
Pre-Conference Programs


Primer on Tumor Immunology and Cancer Immunotherapy™


Immuno-Resistance and Sequencing Symposium

Meet-the-Expert Lunch

Grant Writing Workshop

Friday, Nov. 12
Annual Meeting

36th Annual Meeting

Saturday, Nov. 13
Annual Meeting

36th Annual Meeting

Sunday, Nov. 14
Annual Meeting

36th Annual Meeting